The decision of Cyprus for the vaccine of AstraZeneca – Normally the 2nd dose with one condition

With the AstraZeneca vaccine and in 2nd dose for those who did the 1st of this vaccine Vaccinations continue in Cyprus. The condition is that they did not show any symptoms of serious side effects after the first dose (thrombosis / thrombocytopenia syndrome)

These citizens are invited to attend normally for the 2nd dose of the vaccine, which is particularly important for their shielding against the virus and its mutations, as the Ministry of Health of Cyprus points out, after a meeting of the Scientific Advisory Committee on coronavirus.

At this meeting, as reported by AMPE, the Commission evaluated the vaccination program, the availability of vaccines and the expected receptions of vaccines, the rate of vaccination coverage of the population to date, as well as the issue of serious side effects from vaccinations and related vaccines. episodes that occurred.

With regard to the issue of age restriction on the AstraZeneca vaccine, the majority of TSE members, having taken into account the improved epidemiological picture, the availability of vaccines and the benefit of a smooth continuation of the vaccination program, suggest that Recommendation for preference of mRNA technology vaccines (Pfizer / BioNTech and Moderna) in individuals aged 50 years and under. Therefore, the Ministry of Health adopts the recommendation of the majority of TEU members and urges citizens under the age of 50 to choose vaccine mRNA technology for their vaccination.

The Ministry of Health assures that it closely monitors developments and data emerging in Cyprus and internationally, as well as any new recommendations that may arise from Coreper, and is ready to regularly assess the course of the epidemiological picture of the country and extend the vaccination plan, and take all actions with the primary priority of safeguarding public health and the safety of citizens.